Ripasudil hydrochloride

利舒地尔盐酸盐

Report date: 2025/04/09 15:47:24
NMEFirst In Class

Base Information

Drug NameRipasudil hydrochloride
Drug Alias NameRipasudil Hydrocholoride HydrateGlanatecK-115K-321K-115-R
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRho-associated protein kinase 1 inhibitorsRho-associated protein kinase 2 inhibitors
TargetsRho-associated protein kinase 1Rho-associated protein kinase 2
Therapy Area/IndicationsRetinopathy of PrematurityGlaucomaOcular Hypertension +[8] 
Global Approved IndicationsGlaucomaOcular Hypertension
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2014/09/26
Country/TerritoryCanadaUnited StatesSingapore +[10] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesKowa Dental Health Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesStanford UniversityKowa Research Institute IncKyushu University +[5] 
Inactive CompaniesUniversity Of Erlangen-Nuremberg Medical School
Active IndicationsRetinopathy of PrematurityGlaucomaOcular Hypertension +[6] 
Inactive IndicationsCorneal Endothelial Cell LossCorneal Dystrophies, Hereditary

Other Information

ATC CodeS01EX
Related LinksWikipediaKEGG